CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges
P Grosse‐Gehling, CA Fargeas, C Dittfeld… - The Journal of …, 2013 - Wiley Online Library
The cancer stem cell (CSC) hypothesis, despite the limitations of the currently available
models and assays, has ushered in a new era of excitement in cancer research. The …
models and assays, has ushered in a new era of excitement in cancer research. The …
[HTML][HTML] Ten hub genes associated with progression and prognosis of pancreatic carcinoma identified by co-expression analysis
Z Zhou, Y Cheng, Y Jiang, S Liu, M Zhang… - … journal of biological …, 2018 - ncbi.nlm.nih.gov
Since the five-year survival rate is less than 5%, pancreatic ductal adenocarcinoma (PDAC)
remains the 4th cause of cancer-related death. Although PDAC has been repeatedly …
remains the 4th cause of cancer-related death. Although PDAC has been repeatedly …
[HTML][HTML] Prognostic value of cancer stem cell marker CD133 expression in pancreatic ductal adenocarcinoma (PDAC): a systematic review and meta-analysis
X Li, H Zhao, J Gu, L Zheng - International journal of clinical and …, 2015 - ncbi.nlm.nih.gov
CD133 is one of the most commonly used markers of pancreatic cancer stem cells (CSCs),
which are characterized by their ability for self-renewal and tumorigenicity. Although the …
which are characterized by their ability for self-renewal and tumorigenicity. Although the …
Resveratrol enhances the chemotherapeutic response and reverses the stemness induced by gemcitabine in pancreatic cancer cells via targeting SREBP 1
C Zhou, W Qian, J Ma, L Cheng, Z Jiang… - Cell …, 2019 - Wiley Online Library
Objectives Gemcitabine is a standard treatment for advanced pancreatic cancer patients but
can cause chemoresistance during treatment. The chemoresistant cells have features of …
can cause chemoresistance during treatment. The chemoresistant cells have features of …
MiR-1181 inhibits stem cell-like phenotypes and suppresses SOX2 and STAT3 in human pancreatic cancer
J Jiang, Z Li, C Yu, M Chen, S Tian, C Sun - Cancer letters, 2015 - Elsevier
Recent studies have shown that cancer stem cells (CSCs) play an important role in the
development of pancreatic cancer. Multiple oncogenes and signaling pathways have been …
development of pancreatic cancer. Multiple oncogenes and signaling pathways have been …
Increased expression of DNA repair genes in invasive human pancreatic cancer cells
LA Mathews, SM Cabarcas, EM Hurt, X Zhang… - Pancreas, 2011 - journals.lww.com
Objective: Pancreatic cancer was the fourth leading cause of cancer death in the United
States in 2010. Recurrence of disease after resection occurs because of neoplastic cell …
States in 2010. Recurrence of disease after resection occurs because of neoplastic cell …
Salinomycin inhibits growth of pancreatic cancer and cancer cell migration by disruption of actin stress fiber integrity
Pancreatic ductal adenocarcinoma (PDAC) is characterized by aggressive growth, early
metastasis and high resistance to chemotherapy. Salinomycin is a promising compound …
metastasis and high resistance to chemotherapy. Salinomycin is a promising compound …
CXCR4-A prognostic and clinicopathological biomarker for pancreatic ductal adenocarcinoma: A Meta-Analysis
A Krieg, JC Riemer, LA Telan, HE Gabbert… - PloS one, 2015 - journals.plos.org
Adenocarcinomas of the pancreatic duct (PDAC) are characteristically aggressive tumors
that are extremely challenging to treat as curative surgical resection, the definitive treatment …
that are extremely challenging to treat as curative surgical resection, the definitive treatment …
Polyplex-mediated inhibition of chemokine receptor CXCR4 and chromatin-remodeling enzyme NCOA3 impedes pancreatic cancer progression and metastasis
Y Wang, S Kumar, S Rachagani, BR Sajja, Y Xie… - Biomaterials, 2016 - Elsevier
Pancreatic cancer (PC) is one of the most aggressive malignancies due to intense
desmoplasia, extreme hypoxia and inherent chemoresistance. Studies have implicated the …
desmoplasia, extreme hypoxia and inherent chemoresistance. Studies have implicated the …
Visualization of CD44 and CD133 in normal pancreas and pancreatic ductal adenocarcinomas: non-overlapping membrane expression in cell populations positive for …
H Immervoll, D Hoem, OJ Steffensen… - … of Histochemistry & …, 2011 - journals.sagepub.com
Tumor-initiating cells of pancreatic ductal adenocarcinoma (PDAC) have been isolated
based on expression of either CD133 or CD44. The authors aimed to visualize pancreatic …
based on expression of either CD133 or CD44. The authors aimed to visualize pancreatic …